Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: A potential surrogate end point to assess treatment effectiveness

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 665-672

  Whitacre, Cecilia M ^a   Zborowska, Elizabeth ^a   Willson, James K V ^a   Berger, Nathan A ^a,b  

^a Case Western Reserve University   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE ORANGE; BIOLOGICAL MARKER; CASPASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOPOTECAN;

APOPTOSIS; ARTICLE; COLON CANCER; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; TUMOR BIOPSY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOPSY; CAMPTOTHECIN; CASPASES; CELL DIVISION; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLY(ADP-RIBOSE) POLYMERASES; TIME FACTORS; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033027172     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lautier, D., Lagueux, J., Thibodeau, J., Menard, L., and Poirier, G. G. Molecular and biochemical features of poly(ADP-rihose) metabolism. Mol. Cell. Biochem., 122: 171-193, 1993.
2. Colyer, R. A., Burdette, K. E., and Kidwell, W. R. Poly ADP-ribose synthesis and DNA replication in synchronized mouse L-cells. Biochem. Biophys. Res. Commun., 53: 960-966, 1973.
3. Durkacz, B. W., Omidiji, O., Gray, D. A., and Shall, S. (ADP-ribose)n participates in DNA excision repair. Nature (Lond.), 283: 593-596, 1980.
4. Satoh, M. S., and Lindahl, T. Role of poly(ADP-ribose) formation in DNA repair. Nature (Lond.), 356: 356-358, 1992.
5. Caplan, A. I., and Rosenberg, M. J. Interrelationship between poly(ADP-ribose) syntheis, intracellular NAD levels, and muscle or cartilage differentiation from mesodermal cells of embryonic chick limb. Proc. Natl. Acad. Sci. USA, 72: 1852-1857, 1975.
6. Miwa, M., Oda, K., Segawa, K., Tanaka, M., Irie, S., Yamaguchi, N., Kuchino, T., Shiroki, K., Shimojo, H., Sakura, H., Matsushima, T., and Sugimura, T. Cell density-dependent increase in chromatin-associated ADP-ribosyltransferase activity in simian virus 40-transformed cells. Arch. Biochem. Biophys., 181: 313-321, 1977.
7. Jacobson, E. L., Meadows, R., and Measel, J. Cell cycle perturbations: DNA damage in the presence of ADP-ribosylation inhibitors. Carcinogenesis (Lond.), 6: 711-714, 1985.
8. Masutani, M., Nozaki, T., Wakabayashi, K., and Sugimura, T. Role of poly(ADP-ribose) polymerase in cell cycle checkpoint mechanisms following γ-irradiation. Biochemie, 77: 462-465, 1995.
9. Margolin, N., Raybuck, S. A., Wilson, K. P., Chen, W., Fox, T., Gu, Y., and Livingston, D. G. Substrate and inhibitor specificity of interleukin-1β-converting enzyme and related caspases. J. Biol. Chem., 272: 7223-7228, 1997.
10. Van de Craen, M., Vandenabeele, P., Declercq, W., Van den Brande, I., Van Loo, G., Molemans, F., Schotte, P., van Criekinge, W., Beyaert, R., and Fiers, W. Characterization of seven murine caspase family members. FEBS Lett., 403: 61-69, 1997.
11. Shah, G. M., Shah, R. G., and Poirier, G. G. Different cleavage pattern for poly(ADP-ribose) polymerase during necrosis and apoptosis in HL-60 cells. Biochem. Biophys. Res. Commun., 229: 838-844, 1996.
12. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (Lond.), 371: 346-347, 1994.
13. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
14. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T-T., Yu, V. L., and Miller, D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (Lond.), 376: 37-43, 1995.
15. Whitacre, C. M., and Berger, N. A. Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose) polymerase. Cancer Res., 57: 2157-2163, 1997.
16. He, J., Whitacre, C. M., Xue, L., Berger, N. A., and Oleinick, N. L. Protease activation and cleavage of poly(ADP-ribose) polymerase: an integral part of apoptosis in response to photodynamic treatment. Cancer Res., 58: 940-946, 1998.
17. Wall, M. E., and Wani, M. C. Camptothecin and Taxol. Discovery to Clinic-Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res., 55: 753-760, 1995.
18. Sinha, B. K. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs, 49: 11-19, 1995.
19. Rothenberg, M. L., Kuhn, J. G., Burris, H. A., III, Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M. K., and Von Hoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
20. Slichenmeyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
21. Shimada, W., Yoshino, M., Wakui, A., Nakuo, I., Fatatsuki, K., Sakata, Y., Kambe, M., Toguchi, T., Ogawa, N., and the Gastrointestinal Cancer Study Group. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
22. Pitot, H. C., Wender, D., O'Connell, M. J., Wieand, H. S., and Mailliard, J. A. A phase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc. Am. Soc. Clin. Oncol., 13: 197, 1994.
23. Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A. III, Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., Weiss, G. R., Elfring, G. L., Rinaldi, D. A., Schaaf, L. J., and Von-Hoff, D. D. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol., 14: 1128-1135, 1996.
24. Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., Bonneterre, J., Adenis, A., Burki, F., Mousseau, M., Herait, P., and Mahjoubi, M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol., 15: 251-260, 1997.
25. Whitacre, C. M., Zborowska, E., Gordon, N. H., Mackay, W., and Berger, N. A. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res., 57: 1425-1428, 1997.
26. Hertzberg, R. P., Caranfa, M. J., and Hecht, S. M. On the mechanism of topoisomerase I inhibition: evidence for binding to an enzyme-DNA complex. Biochemistry. 28: 4629-4638, 1989.
27. McBain, J. A., Weese, J. L., Meisner, L. F., Wolberg, W. H., and Willson, J. K. V. Establishment and characterization of human colorectal cancer cell lines. Cancer Res., 44: 5813-5821, 1984.
28. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase 1 inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
29. 2+-mediated endonuclease activation. Science (Washington DC), 242: 256-259, 1988.
30. Negri, C., Bernardi, R., Braghetti, A., Astaldi Ricotti, G. C. B., and Scovassi, A. I. The effect of the chemotherapeutic drug VP-16 on poly(ADP-ribosylation) in apoptotic HeLa cells. Carcinogenesis (Lond.), 14: 2559-2564, 1993.
31. He, D., Mu, Z-M., Le, X., Hsieh, J-T., Pong, R-C., and Chung, L. W. K. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res., 57: 1868-1872, 1997.
32. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
33. Ranjit, G. B., Cheng, M-F., Mackay, W., Whitacre, C. M., Berger, J. S., and Berger, N. A. Poly(adenosine diphosphoribose) polymerase in peripheral blood leukocytes from normal donors and patients with malignancies. Clin. Cancer Res., 1: 223-234, 1995.
34. Creemers, G. J., Wanders, J., Gamucci, T., Vallentin, S., Dirix, L. Y., Schoffski, P., Hudson, I., and Verweij, J. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. Ann. Oncol., 6: 844-846, 1995.
35. Armand, J. P., Ducreaux, M., Mahjoubi, M., Abigerges, D., Bugat, R., Chabot, G., Herait, P., de Forni, M., and Rougier, P. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur. J. Cancer. 31A: 1283-1287, 1995.
36. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
37. Lamb, J. R., and Friend, S. H. Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. Nat. Med., 3: 962-963, 1997.
38. Wheeler, J. A., Stephens,L. C., Tornos, C., Eifel, P. J., Ang, K. K., Milas, L., Allen, P. K., and Meyn, R. E. ASTRO research fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 32: 1487-1493, 1995.